NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

Thanks Captain. I mostly parasite on others great DD - like biosectinvestor here -I guess I'm mostly good at collecting and distributing and make stuff easily available. It is necessary when we lack a good way of organizing good DD.

I'm at a loss at "people" - like AF - still trying to sow doubt about the DCVax-L and Keytruda trial.

I guess they know, that this is the big Tzar bomba, that could valuate NWBO to the stratosphere, so they have to somehow still question this, even though it seems like rational seppuku.

It IS quite easy.

There are 3 UCLA SPORE projects.

https://trp.cancer.gov/spores/abstracts/ucla_brain.htm

The first one is the combo trial between DCvax-L and Keytruda

https://trp.cancer.gov/spores/abstracts/ucla_brain.htm#h03

Project 1: Active immunotherapy combined with checkpoint modulation for glioblastoma
Project Co-Leaders:
Robert M. Prins, PhD (Basic Co-Leader)
Linda M. Liau, MD, PhD, MBA (Clinical Co-Leader)

It says directly:

"... in conjunction with tumor lysate-pulsed DC vaccination (DCVax-L)"

This is an old description. Look at aim 3

Aim 3: To develop predictive immunological and imaging biomarkers of response in recurrent glioblastoma patients enrolled in a Phase II clinical trial of DCVax-L +/- Nivolumab.

This is the original clinical trial that was setup with BMYs Opdivo (Nivolumab)

"A Phase II Clinical Trial Evaluating Combination Therapy Using DCVax-L (Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen) and Nivolumab (an Anti-PD-1 Antibody) for Subjects With Recurrent Glioblastoma Multiforme"
https://clinicaltrials.gov/ct2/show/NCT03014804

But that was withdrawn,

If we look at Linda Liaus most recent slides for the SPORE PROJECT 1, we can see, that DCVax is mentioned here



in a later slide we can see the word PEMBRO (short for Pembrolizumab aka Keytruda) is mentioned for the PD-1 inhibitor



So the combo trial with DCVax-L and Keytruda exchanged the combo trial with Nivolumab (Opdivo) and that equals the SPORE 1 PROJECT at UCLA.

If we look at the patent

"COMBINATIONS OF CHECKPOINT INHIBITORS AND THERAPEUTICS TO TREAT CANCER"

We can see that the last two in the "inventors list" are the same two UCLA persons Liau and Prins that are the SPORE 1 PROJECT UCLA collaborators.



Look at the patent



The original inventors include key NWBO personnel

“Inventor: Marnix Leo BOSCH, James Kelly GANJEI, Linda F. POWERS, Linda M. Liau, Robert M. PRINS”

The rights don’t expire. The patent is assigned and that is that. There has been no reassignment back to UCLA.

The definitive assignment is what is in the patent database maintained by the government.

Invention means these parties all hold equal rights in the invention. We’d have knowledge if the application, which has not been granted yet, were to change the assignees, and there is likely a clear agreement between all the parties as to who has what exact rights from the INVENTORS:

“Current Assignee: RevImmune Inc University of California Northwest Biotherapeutics LLC Cognate Bioservices Inc”

The University retains research rights, as does NWBO, and improvements likely accrue according to the way the original assignment agreement stipulates. None of the other parties has ever represented that it has the rights to market DCVax as a commercial product with the FDA or other regulators except NWBO. There is no indication that any of this has changed.

The patent is global



Annual shareholders meeting 2018.

Linda Powers talk about the combo trial NWBO will do with Keytruda.

"That trial, which we did announce publicly and has been approved by Merck, and those agreements were signed and all that ..."

NWBO has all rights.

I like flippers comment here



What can I say, but

GAME OVER MAN!

I can't lie about shorters chances, but they have my sympathies.